Cargando…
Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction
BACKGROUND: The majority of lung cancer(LC) patients are diagnosed at advanced stage with a poor prognosis. However, there is still no ideal diagnostic and prognostic prediction model for lung cancer. METHODS: Data of CEA, CYFRA21-1 and NSE test of patients with LC and benign lung diseases (BLDs) or...
Autores principales: | Yuan, Jingmin, Sun, Yan, Wang, Ke, Wang, Zhiyi, Li, Duo, Fan, Meng, Bu, Xiang, Chen, Jun, Wu, Zhiquan, Geng, Hui, Wu, Jiamei, Xu, Ying, Chen, Mingwei, Ren, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214980/ https://www.ncbi.nlm.nih.gov/pubmed/35729538 http://dx.doi.org/10.1186/s12885-022-09728-5 |
Ejemplares similares
-
Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients
por: Zhou, Wenwen, et al.
Publicado: (2021) -
Retracted: Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients
por: Healthcare Engineering, Journal of
Publicado: (2023) -
Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis()()()
por: Wang, Jingbo, et al.
Publicado: (2018) -
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
por: Dal Bello, M. G., et al.
Publicado: (2019) -
Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer
por: Zhang, Zhi-Hui, et al.
Publicado: (2015)